New Two-Pronged attack tested against tough cervical cancers
NCT ID NCT07244965
Summary
This study is testing if adding a new immunotherapy drug, Ivonescimab, to standard chemotherapy before radiation treatment is safe and more effective for women with high-risk, locally advanced cervical cancer. The goal is to better control the cancer and prevent it from coming back. About 42 participants will receive the drug combination followed by standard chemoradiation, and researchers will track their health outcomes and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.